ARCHIVES

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Approvals: Lymphoseek Label Updated to Include Head and Neck SCC

June 27, 2014

Memphis CCOP Withdrawn, Says Lack Of Patient Benefits, Excess Tests Discouraged Local Physicians

November 16, 1984

FDA, NIH Streamline Approvals For Gene Therapy Studies

June 16, 1995

In Brief: NCI Recieves Two Proposals For Antineoplaston Trials, None For Children; Stubble Elected To NAS

June 19, 1992

Pat Barr, Early NBCC Activist, Dead.

June 27, 2003

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

June 24, 2011